CD200 is expressed in a number of malignancies and has been associated with poor outcome, including melanoma, acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia, renal carcinoma, bladder cancer, ovarian carcinoma, and colon carcinoma (28, 71–75). Here, CD200 is linked to urinary bladder cancer.